June 27, 2016 05:54 AM EDTUpdated September 18, 11:49 PM
Bioregnum
Opinion

The Zer­houni rule: “Every com­pa­ny that ac­quires a plat­form com­pa­ny kills it.”

Why Medi­va­tion makes the per­fect biotech takeover tar­get for Sanofi

Last Jan­u­ary at the J.P. Mor­gan con­fab, I had a chance to sit …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

No­vo claims high-dose Phase 3 We­govy win but sales im­pact might be mut­ed

An­oth­er US biotech emerges with drug can­di­date from Chi­na-based Keymed

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times